Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cyclic peptide therapies - advanceCor

X
Drug Profile

Research programme: cyclic peptide therapies - advanceCor

Latest Information Update: 10 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator advanceCor
  • Class Cyclic peptides; Eye disorder therapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Graves' disease

Most Recent Events

  • 10 Sep 2024 Advancecor has patent protection for 'Cyclic peptides for the treatment of graves' disease' in European Union
  • 10 Sep 2024 Preclinical trials in Graves' disease in Germany (Parenteral) prior to September 2024 (advanceCOR pipeline, September 2024)
  • 10 Sep 2024 German Federal Institute for Drugs and Medical Devices (BfArM) and the European Medicines Agency approves clinical trial application for cyclopeptide in treatment of Grave's disease in Germany (advanceCor pipeline, September 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top